Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

NCT01687387 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: IPH2102 at 0.1 mg/kg
DRUG: IPH2102 at 1 mg/kg
DRUG: Placebo (normal saline solution)

Sponsor

Innate Pharma